Biofrontera AG

B8FK

DE000A4BGGM7

Pharmaceuticals

End-of-day quote Xetra Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
2.58 ^EUR	-1.15%		-13.71%	-69.36%

06-24	Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp	CI
05-31	Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Biofrontera AG Announces Revenue Results for the Fourth Quarter of 2021

January 13, 2022 at 02:26 pm

Biofrontera AG announced revenue results for the fourth quarter of 2021. For the period, the company reported total revenue was between EUR 10.2 and EUR 10.4 million, compared to EUR 9.5 million in the fourth quarter of 2020.

Latest news about Biofrontera AG

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp	06-24	CI
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024	05-31	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $7.9M, vs. Street Est of $10.9M	05-15	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	03-11	MT
Medicus Pharma Names COO	03-05	MT
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $8.9M, vs. Street Est of $8.4M	11-09	MT
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	10/10/23	MT
Biofrontera Says Sun Pharmaceutical Alleging Breach of Contract In Lawsuit	03/10/23	DJ
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23	CI
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	28/08/23	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q2 Revenue $5.8M	11/08/23	MT
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	10/08/23	MT
Top Premarket Decliners	21/07/23	MT
Biofrontera Launches Novel Belixos Active Care	05/07/23	CI
Biofrontera to Effect 1-for-20 Reverse Stock Split	03/07/23	MT
Wall Street Set to Open Lower; Housing Starts Rise More Than Expected	20/06/23	MT
Transcript : Biofrontera AG, Q1 2023 Earnings Call, May 31, 2023	31/05/23
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2023	31/05/23	CI
Biofrontera AG Completes Patient Recruitment of Ameluz Phase I Trial	17/05/23	CI
Biofrontera Says it Obtained US Patent for New Photodynamic Therapy Protocol	15/05/23	MT
Earnings Flash (BFRI) BIOFRONTERA Reports Q1 Revenue $8.7M, vs. Street Est of $9.2M	12/05/23	MT
Biofrontera Enters $6.5 Million Line of Credit With MidCap Business Credit	11/05/23	MT
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23	CI

Chart Biofrontera AG

Duration

Period

More charts

Company Profile

Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIOFRONTERA AG	-69.36%	17.06M
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+32.92%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ASTRAZENECA PLC	+13.30%	243B
NOVARTIS AG	+16.37%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals

Biofrontera AG

Equities

B8FK

DE000A4BGGM7

Pharmaceuticals

Biofrontera AG Announces Revenue Results for the Fourth Quarter of 2021

Latest news about Biofrontera AG

Chart Biofrontera AG

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals